search
Back to results

Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection

Primary Purpose

Leukemia, Transplantation, Hematopoietic Stem Cell

Status
Unknown status
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Caspofugin based combination therapy
Sponsored by
Shanghai Jiao Tong University School of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Leukemia focused on measuring caspofungin, IFI, allogeneic hematopoietic stem cell transplantation

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • adult patient undergoing allogeneic hematopoietic stem cell transplantation
  • age 18-55 years
  • with inform consent
  • no contraindication for allogeneic transplantation: active infection, allergy to FLu/Bu/CTX, liver and renal function damage
  • HLA mismatched related (3~5/6) or unrelated donors (at least 8/10)
  • proven or probable IFI

Exclusion Criteria:

  • age less than 18 years or over 56 years
  • HLA mismatched related donor
  • liver function/renal function damage (over 2 X upper normal range)
  • with mental disease

Sites / Locations

  • Blood & Marrow Transplantation Center, RuiJin HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Caspofugin based combination therapy

Arm Description

Caspofugin based combination therapy: Patients will recieve caspofungin with voriconazole or amphotericin B

Outcomes

Primary Outcome Measures

Favorable response rate

Secondary Outcome Measures

Overall survival

Full Information

First Posted
December 26, 2011
Last Updated
May 9, 2016
Sponsor
Shanghai Jiao Tong University School of Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT01501708
Brief Title
Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection
Official Title
Phase II Study of Caspofungin Based Combined Anti-fungal Therapy for Patients With Proven or Probable Invasive Fungal Infection After Allogeneic Stem Cell Transplantation From HLA-matched Unrelated or HLA-mismatched Related Donors
Study Type
Interventional

2. Study Status

Record Verification Date
May 2016
Overall Recruitment Status
Unknown status
Study Start Date
December 2011 (undefined)
Primary Completion Date
June 2017 (Anticipated)
Study Completion Date
December 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shanghai Jiao Tong University School of Medicine

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
In this prospective phase II observational study, we plan to assess the efficacy and tolerability of caspofungin based combined anti-fungal therapy for proven or probable IFI in a group of patients received allo-HSCT transplantation with high risk of IFI: HLA matched unrelated donor or mismatched donor conditioning with ATG containing regimen or present III-IV aGVHD or extensive GVHD undergoing high-dose steroid treatment.
Detailed Description
Patients will recieve caspofungin with either voriconazole or amphotericin B as combination therapy for fungal infection

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leukemia, Transplantation, Hematopoietic Stem Cell
Keywords
caspofungin, IFI, allogeneic hematopoietic stem cell transplantation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
55 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Caspofugin based combination therapy
Arm Type
Experimental
Arm Description
Caspofugin based combination therapy: Patients will recieve caspofungin with voriconazole or amphotericin B
Intervention Type
Drug
Intervention Name(s)
Caspofugin based combination therapy
Other Intervention Name(s)
caspofungin + voriconazole or amphotericin B
Intervention Description
Caspofungin: 70 mg on the first day of therapy, followed by 50 mg q.d. All patients received azoles as prophylaxis (fluconazole as prophylaxis and itraconazole or voriconazole as secondary prophylaxis), combination with liposomal amphotericin B at a dosage 3mg/kg q.d will be given. In case of renal function damage, combination with voriconazole 6mg/kg followed by 4 mg/kg b.i.d. will be given.
Primary Outcome Measure Information:
Title
Favorable response rate
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Overall survival
Time Frame
12 weeks, 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: adult patient undergoing allogeneic hematopoietic stem cell transplantation age 18-55 years with inform consent no contraindication for allogeneic transplantation: active infection, allergy to FLu/Bu/CTX, liver and renal function damage HLA mismatched related (3~5/6) or unrelated donors (at least 8/10) proven or probable IFI Exclusion Criteria: age less than 18 years or over 56 years HLA mismatched related donor liver function/renal function damage (over 2 X upper normal range) with mental disease
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jiong HU, M.D.
Phone
86-21-64370045
Ext
601818
Email
hujiong@medmail.com.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ling Wang, M.D.
Organizational Affiliation
Rui Jin Hospital, Shanghai JiaoTong University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Blood & Marrow Transplantation Center, RuiJin Hospital
City
Shanghai
ZIP/Postal Code
200025
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ling Wang, M.D
Phone
86-21-64370045
Ext
601818

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection

We'll reach out to this number within 24 hrs